Anaveon is starting efficacy trials with ANV419, their powerful and selective IL-2 agonist.
Andreas Katopodis, Co-founder and CEO of Anaveon (Image: Jasmin Rei)
One of our portfolio companies, Anaveon AG, announces FDA Safe to proceed letter for Investigational New Drug (IND) Application for its no-alpha IL-2 agonist, ANV419
Anaveon, a clinical-stage immuno-oncology company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the IND application for ANV419-101, a Phase I/II mono treatment dose confirmation and combination dose-finding, global study, in patients with advanced cutaneous melanoma. ANV419, a potent IL-2R agonist, preferentially proliferates CD8 and NK cells over regulatory T cells. The safety profile seen to date will allow for the administration of doses inducing maximal pharmacodynamic effects. The most frequent drug-related AEs seen in an ongoing trial include mild Grade 1 chill and low-grade fever a few hours after dosing, which resolved with antipyretic treatment.
“We are excited to bring ANV419 to patients who are most likely to benefit from a truly IL-2R-selective high-dose IL-2 approach. We look forward to expanding our clinical program to the US and maximizing the therapeutic potential of ANV419 for patients suffering from cancer.” said Christoph Bucher, Chief Medical Officer at Anaveon.
About the Phase I/II Clinical Trial The clinical trial is a Phase I/II multiple arm, open-label study in patients with unresectable or metastatic cutaneous melanoma. The study will be a sequential, multi-part clinical trial to evaluate the safety and efficacy of different monotherapy doses of ANV419, as well as in combination with anti-PD1 or anti-CTLA4. Up to 130 patients will be enrolled in the clinical trial.
